Empaveli Injection, Solution
Product Images NDC 73606-010

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Empaveli (NDC 73606-010). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apellis Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Pegcetacoplan 01)

Chemical structure diagram showing the molecular arrangement of the active ingredient Pegcetacoplan. The diagram includes peptide chains with amino acid abbreviations and specific chemical bonds, depicting the structure of Pegcetacoplan as represented in the product Empaveli.*

FDA Label Image

Figure 1 (Pegcetacoplan 02)

A line graph comparing changes from baseline in hemoglobin levels over time between Empaveli and Eculizumab treatments. The x-axis shows analysis visits at weeks 2, 4, 6, 8, 12, and 16. The y-axis shows change from baseline in grams per deciliter. Empaveli data points are represented by solid squares with a slight downward trend, while Eculizumab data points are represented by open triangles showing an initial decrease and leveling off below baseline. Error bars indicate variability at each time point.*

FDA Label Image

Figure A (Pegcetacoplan 03)

An instructional diagram showing components for subcutaneous injection setup, including a needleless transfer device or transfer needle, infusion tubing, a compatible syringe for infusion pump, alcohol swipes, gauze and tape or transparent dressing, and a sharps container for disposal.*

FDA Label Image

Figure B (Pegcetacoplan 04)

Empaveli 1080 mg/20 mL injection solution in a vial, labeled for subcutaneous use, manufactured by Apellis Pharmaceuticals, Inc. The image shows a hand holding the vial, with a round callout indicating space for lot number and expiration date details.*

FDA Label Image

Figure C (Pegcetacoplan 05)

An illustration showing a hand removing the flip cap from the top of a vial labeled Empaveli (pegcetacoplan). The vial contains 1080 mg/20 mL solution for subcutaneous injection, as indicated on the label.*

FDA Label Image

Figure D (Pegcetacoplan 06)

An illustration showing two hands preparing a syringe for injection. One hand holds the syringe barrel while the other hand is pulling back the plunger, indicated by a downward arrow, suggesting the drawing or mixing of medication within the syringe.*

FDA Label Image

Figure E (Pegcetacoplan 07)

An instructional illustration showing a person's hands preparing a syringe to withdraw medication from a vial labeled Empaveli (pegcetacoplan) injection, solution, 1080 mg/20 mL. The syringe is inserted into the vial's stopper, with measured markings visible on the syringe barrel.*

FDA Label Image

Figure F (Pegcetacoplan 08)

An illustration showing a hand holding a vial labeled Empaveli (Pegcetacoplan) 1080 mg/20 mL injection solution. The vial is inverted and being used to fill a syringe, indicating preparation for subcutaneous administration.*

FDA Label Image

Figure G (Pegcetacoplan 09)

An instructional illustration showing a hand holding a vial and drawing injection solution into a syringe. An arrow indicates the downward motion of inserting the syringe needle into the vial to extract the solution, related to the subcutaneous injection preparation for Empaveli (Pegcetacoplan) 1080 mg/20mL.*

FDA Label Image

Figure H (Pegcetacoplan 10)

An illustration showing a hand holding a syringe filled with liquid, with the needle being attached to or detached from a needle cover. The image likely demonstrates the preparation or handling of an injectable solution for subcutaneous use.*

FDA Label Image

Figure I (Pegcetacoplan 11)

An instructional illustration showing a person's hands preparing a syringe for injection. One hand holds the syringe upright with measurement markings visible, while the other hand is removing the cap from the needle with a downward arrow indicating the direction of removal.*

FDA Label Image

Figure J (Pegcetacoplan 12)

An instructional illustration showing a hand twisting the cap off the needle end of a syringe, which is held in another hand. The image likely demonstrates a step in preparing an injectable solution for subcutaneous administration.*

FDA Label Image

Figure K (Pegcetacoplan 13)

An anatomical diagram indicating recommended injection sites for a subcutaneous injection. The marked areas include the upper arm, abdomen, hip, and thigh, shown on a front-facing human figure.*

FDA Label Image

Figure L (Pegcetacoplan 14)

An instructional illustration showing two subcutaneous injection sites on the abdomen. The sites are labeled to be at least 3 inches apart, demonstrating proper spacing for Empaveli (pegcetacoplan) injection placement.*

FDA Label Image

Figure M (Pegcetacoplan 15)

An instructional illustration showing a hand cleaning the skin around the navel with a wiping pad, demonstrating preparation for a subcutaneous injection.*

FDA Label Image

Figure N (Pegcetacoplan 16)

An instructional illustration showing a person administering a subcutaneous injection by pressing a syringe or autoinjector into the skin. The image highlights the technique of pulling back the skin slightly with one hand while holding the injection device with the other, with an arrow indicating the direction of skin pulling.*

FDA Label Image

Figure O (Pegcetacoplan 17)

Illustration showing a subcutaneous infusion set attached to a person's abdomen, demonstrating the application site for injection or infusion. The device is secured with an adhesive patch on the skin.*

FDA Label Image

Figure P (Pegcetacoplan 18)

An instructional illustration showing a hand pouring vial contents into a black container with a wide opening. The container has a label with text and graphics, and a cord or tube attached to its side, suggesting a medical or pharmaceutical use.*

FDA Label Image

Principal Display Panel (1,080 mg/20 mL Vial Carton)

Empaveli 1080 mg/20 mL (54 mg/mL) injection solution for subcutaneous infusion, manufactured by Apellis Pharmaceuticals, Inc. The packaging includes dosage storage instructions, vial contents, and the requirement to dispense the enclosed medication guide. The label also indicates it is a single-dose vial and product of Switzerland.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.